Fig. 7.
BCR-ABL suppresses p38 MAPK activity and up-regulates BCL-XL independent of each other.
Conditions are identical to Figure 6, panels A and C, with an additional total ERK2 antibody. These molecular pathways were analyzed from 2 independent experiments with similar results.
